Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases

被引:11
作者
Dong, Jing [1 ]
Zhao, Hongtao [1 ]
Zhou, Ting [1 ]
Spiliotopoulos, Dimitrios [1 ]
Rajendran, Chitra [2 ]
Li, Xiao-Dan [2 ]
Huang, Danzhi [1 ]
Caflisch, Amedeo [1 ]
机构
[1] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland
[2] Paul Scherrer Inst, Lab Biomol Res, CH-5232 Villigen, Switzerland
基金
瑞士国家科学基金会;
关键词
Eph kinases; protein crystallography; structure-based drug design; fragment-based docking; DISCOVERY; DESIGN; DOCKING;
D O I
10.1021/ml500355x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have solved the crystal structures of the EphA3 tyrosine kinase in complex with nine small-molecule inhibitors, which represent five different chemotypes and three main binding modes, i.e., types I and I-1/2 (DFG in) and type II (DFG out). The three structures with type I-1/2 inhibitors show that the higher affinity with respect to type I is due to an additional polar group (hydroxyl or pyrazole ring of indazole) which is fully buried and is involved in the same hydrogen bonds as the (urea or amide) linker of the type II inhibitors. Overall, the type I and type II binding modes belong to the lock-and-key and induced fit mechanism, respectively. In the type II binding, the scaffold in contact with the hinge region influences the position of the Phe765 side chain of the DFG motif and the orientation of the Gly-rich loop. The binding mode of Birb796 in the EphA3 kinase does not involve any hydrogen bond with the hinge region, which is different from the Birb796/p38 MAP kinase complex. Our structural analysis emphasizes the importance of accounting for structural plasticity of the ATP binding site in the design of type II inhibitors of tyrosine kinases.
引用
收藏
页码:79 / 83
页数:5
相关论文
共 26 条
[1]   Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors [J].
Bardelle, Catherine ;
Barlaam, Bernard ;
Brooks, Nigel ;
Coleman, Tanya ;
Cross, Darren ;
Ducray, Richard ;
Green, Isabelle ;
Lambert-van der Brempt, Christine ;
Olivier, Annie ;
Read, Jon .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (21) :6242-6245
[2]   Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series [J].
Barlaam, Bernard ;
Ducray, Richard ;
Lambert-van der Brempt, Christine ;
Ple, Patrick ;
Bardelle, Catherine ;
Brooks, Nigel ;
Coleman, Tanya ;
Cross, Darren ;
Kettle, Jason G. ;
Read, Jon .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (08) :2207-2211
[3]   Therapeutic targeting of EPH receptors and their ligands [J].
Boyd, Andrew W. ;
Bartlett, Perry F. ;
Lackmann, Martin .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (01) :39-62
[4]   Eph receptor tyrosine kinases in cancer stem cells [J].
Chen, Jin ;
Song, Wenqiang ;
Amato, Katherine .
CYTOKINE & GROWTH FACTOR REVIEWS, 2015, 26 (01) :1-6
[5]  
Chen Jin, 2008, Cancer Res, V68, P10031, DOI 10.1158/0008-5472.CAN-08-3010
[6]   Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors [J].
Choi, Yongmun ;
Syeda, Farisa ;
Walker, John R. ;
Finerty, Patrick J., Jr. ;
Cuerrier, Dominic ;
Wojciechowski, Amy ;
Liu, Qingsong ;
Dhe-Paganon, Sirano ;
Gray, Nathanael S. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) :4467-4470
[7]   Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics [J].
Gucciardo, Erika ;
Sugiyama, Nami ;
Lehti, Kaisa .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2014, 71 (19) :3685-3710
[8]   EPH receptor/ephrin system: in the quest for novel anti-angiogenic therapies: Commentary on Hassan-Mohamed etal., Br J Pharmacol 171: 5195-5208 [J].
Hatziapostolou, M. ;
Polytarchou, C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (18) :4597-4599
[9]   Library screening by fragment-based docking [J].
Huang, Danzhi ;
Caflisch, Amedeo .
JOURNAL OF MOLECULAR RECOGNITION, 2010, 23 (02) :183-193
[10]   Regulation of angiogenesis by Eph-Ephrin interactions [J].
Kuijper, Sanne ;
Turner, Christopher J. ;
Adams, Ralf H. .
TRENDS IN CARDIOVASCULAR MEDICINE, 2007, 17 (05) :145-151